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Background: We previously showed that the Vibrio cholerae ghost platform (VCG; empty V. cholerae cell envelopes)
is an effective delivery system for vaccine antigens promoting the induction of substantial immunity in the absence
of external adjuvants. However, the mechanism by which these cell envelopes enhance immunity and stimulate a
predominantly Th1 cellular and humoral immune response has not been elucidated. We hypothesized that the
immunostimulatory ability of VCG involves dendritic cell (DC) activation.
Objective: The aims of this study were: a) to investigate the ability of DCs [using mouse bone marrow-derived
DCs (BMDCs) as a model system] to take up and internalize VCGs; b) to evaluate the immunomodulatory effect
of internalized VCGs on DC activation and maturation and their functional capacity to present chlamydial antigen to
naïve and infection-sensitized CD4+ T cells and; c) to evaluate the ability of VCGs to enhance the protective immunity
of a chlamydial antigen.
Results: VCGs were efficiently internalized by DCs without affecting their viability and modulated DC-mediated immune
responses. VCG-pulsed DCs showed increased secretion of proinflammatory cytokines and expression of co-stimulatory
molecules associated with DC maturation in response to stimulation with UV-irradiated chlamydial elementary bodies
(UV-EBs). Furthermore, this interaction resulted in effective chlamydial antigen presentation to infection-sensitized but
not naïve CD4+ T cells and enhancement of protective immunity.
Conclusions: The present study demonstrated that VCGs activate DCs leading to the surface expression of co-stimulatory
molecules associated with DC activation and maturation and enhancement of protective immunity induced by a
chlamydial antigen. The results indicate that the immunoenhancing activity of VCG for increased T-cell activation
against antigens is mediated, at least in part, through DC triggering. Thus, VCGs could be harnessed as immunomodulators
to target antigens to DCs for enhancement of protective immunity against microbial infections.
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Chlamydia trachomatis is a major cause of sexually trans-
mitted infection, which if untreated often lead to severe
complications, such as pelvic inflammatory disease, ectopic
pregnancy and tubal infertility [1,2] A vaccine to prevent
chlamydial infection is urgently needed but none currently* Correspondence: feko@msm.edu
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so far yielded inadequate protection [3]. This failure to
afford sterilizing immunity may partly be due to their
inability to induce a favorable immunostimulatory and
cytokine environment. Immunomodulators (adjuvants)
act by activating the innate immune system to provide
an adequate co-stimulatory and favorable cytokine en-
vironment to support the stimulation of the desired
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made of attenuated or killed pathogens, thus containing
naturally a number of signals able to activate the innate
immune response [4,5]. Subunit vaccines on the other
hand rely on the incorporation of effective adjuvants to
modulate immunity [6]. Although many substances are
under investigation for their effectiveness as adjuvants,
none is currently approved for human use [7]. The FDA
approved Aluminum salts (alum) adjuvants induce mainly
humoral immunity and is not very effective at enhancing
cell-mediated immune responses [8,9]. There is thus a
need to develop new and effective adjuvants that can be
used in humans.
Vibrio cholerae ghosts (VCGs) are empty bacterial cell
envelopes devoid of cytoplasmic contents and cholera
toxin and are generated by the genetic inactivation of
Vibrio cholerae cells that results in expulsion of cyto-
plasmic contents [10]. VCGs share the functional and
antigenic determinants of the envelope with their living
counterparts [10]. They are attractive for use, as non-
living vaccine delivery vehicles because they are non-
toxic, maintain the structural and functional integrity of
expressed antigens, and are excellent for delivery of vac-
cine antigens to primary antigen-presenting cells [11].
We previously showed VCG-based subunit vaccines in-
duced significant chlamydial immunity in the absence of
external adjuvants suggesting VCGs possess potent adju-
vant properties [12,13]. However, the mechanism of
VCG-mediated immune enhancement has not been de-
lineated. We hypothesized that the immunostimulatory
ability of VCG is exerted via dendritic cell (DC) activa-
tion. DCs are the most potent antigen presenting cells
(APCs) and efficiently acquire and present antigens to
stimulate adaptive immunity [14] through expression of
a combination of cell surface and secreted molecules
that influence the type of immune response stimulated.
Secretion of T-helper type-1 (Th1)-driving cytokines,
such as interleukin-12 (IL-12), by DCs favors induction
of Th1-biased responses. In this regard, we previously
showed that Chlamydia-pulsed IL-10-deficient DCs pro-
duced sterilizing, long-term chlamydial immunity fol-
lowing adoptive immunization of mice indicating that
they possessed the necessary antigenic, costimulatory
and immunomodulatory machinery for inducing an opti-
mal protective immunity [15].
To clarify the cellular and molecular basis of the im-
munomodulatory action of VCGs, the present study will:
a) investigate the ability of mouse bone marrow-derived
DCs (BMDCs) to take up and internalize VCGs; b) de-
termine the effect of internalized VCGs on DC activa-
tion, maturation and differentiation and; c) evaluate the
immunomodulatory ability of VCGs to enhance the
functional capacity of BMDCs to present chlamydial
antigen to naïve and infection-sensitized CD4+ T cellsand stimulate T cell proliferation. We show that VCGs
were efficiently internalized by DCs without affecting
their viability. Also, VCG-pulsed DCs showed increased
secretion of proinflammatory cytokines and expression of
co-stimulatory molecules associated with DC maturation
following stimulation with UV-EBs. Furthermore, this
interaction resulted in effective chlamydial antigen presen-
tation to infection-sensitized but not naïve CD4+ T cells,
as indicated by enhanced T cell proliferation and secretion
of Th1-type cytokines.
Methods
Chlamydia stocks and antigens
Stock preparations of C. trachomatis serovar D strain
were generated by propagating elementary bodies (EBs)
in HeLa cells as previously described [16]. All stocks
were titrated on HeLa cell monolayer’s followed by puri-
fication of EBs over renografin gradients [16] and stored
at −70°C. Chlamydial antigens were prepared by UV-
inactivation of EBs for 3 h and stored at −70°C.
Mice
All mice used in these studies were of the C57BL/6
strain (female, aged 6 to 8 weeks) from The Jackson
Laboratory (Bar Harbor, ME). They were housed in the
animal facility of Morehouse School of Medicine (MSM)
and animal study protocols were performed in compliance
with Institutional Animal Care and Use Committee
(IACUC) (IACUC protocol #09-18) and prescribed federal
guidelines.
Production of Vibrio cholerae ghosts (VCG)
Production of VCG was carried out essentially as described
previously [10]. Briefly, competent Vibrio cholerae H1 cells
harboring the lysis plasmid pDKLO1 were grown in brain
heart infusion medium (BHI) at 37°C to mid-log phase.
Cell lysis was achieved by the addition of 3-methyl
benzoate to induce gene E expression from the Pm
promoter, which results in rapid de-repression and protein
E-mediated lysis. The extent and rate of lysis was followed
by measuring the absorbance of the lysing culture at
600 nm and quantified as decrease in turbidity per unit of
time. At the end of lysis cultures were harvested, washed
with phosphate-buffered saline (PBS) or a low ionic buffer
and lyophilized. Lyophilized VCGs were weighed and the
number of CFU per milligram of VCG was estimated
based on the total number of CFU in the culture medium
at the highest absorbance attained before lysis. Ghost
preparations were stored at room temperature until use.
Dendritic cell (DC) isolation and culture
DCs were generated from the bone marrow (BMDC) of
6 week-old C57BL/6 mice as described previously [17]
using IL-4 and GM-CSF. Purified DCs at a concentration
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UV-EB (at an MOI of 10) in 24-well for 24 h. Culture
supernatants were collected and assayed for cytokines
(IL-12, IL-10, IL-4 and TNF-α) and harvested cells were
stained for flow cytometric analysis.
JAWS II cells (ATCC, CRL-1194; Manassas, VA), an
immortalized immature dendritic cell line, which was
established from bone marrow cells of a p53-knockout
C57BL/6 mouse [18] were used for VCG uptake experi-
ments. Cells were cultured in complete culture medium
consisting of IMDM with 10% FCS, 4 mM L-glutamine,
10 U/ml penicillin and 100 μg/ml streptomycin, 0.5 mM
2-ME, 1 mM sodium pyruvate, and 5 ng/ml murine
GM-CSF essentially as described [19].
Uptake of VCG by DCs and confocal microscopy
VCGs were labeled using Alexa Fluor® 594 Protein label-
ing kit (Life Technologies, Grand Island, NY) according
to the manufacturer’s instructions with minor modifica-
tions. Briefly, the lyophilized VCGs resuspended in PBS
were transferred to the vial of reactive dye and the reac-
tion mixture was stirred for 1 hour at room temperature.
Following the conjugation reaction the unbound dye was
washed off via centrifugation instead of passing through
the gel filtration column provided for soluble proteins.
JAWS II cells (5 × 105 cells/ml) were plated on Lab Tek
II Chamber slides (Thermo Scientific, Pittsburgh, PA)
and incubated with 100 mg/ml of Alexa 594-labeled
VCG for 45 min at 37°C/5% CO2 to measure specific
uptake. After washing three times with ice cold PBS
containing 2% BSA (PBS-BSA) to remove free non-
internalized VCG, the cells were fixed in cold acetone
for 10 min at room temperature and again washed
three times with PBS-BSA. The cells were then incu-
bated for 1 h with biotin-labeled anti-mouse CD11c
antibodies and streptavidin-conjugated Alexa 488 (Life
Technologies, Grand Island, NY) for 1 h. Following
washing with PBS-BSA, the slides were mounted in a
drop of Vectashield medium (Vector Labs, Burlingame,
CA). A Leica TCS SP5 Confocal Microscopy System
(Leica Microsystems; Bannockburn, IL) equipped with
a 40× and 63×/1.40 NA oil-immersion objectives were
used to scan the slides and then analyzed using the
Leica Application Suite, Advanced Fluorescence (LAS
AF) and Image J softwares.
Assessment of DC viability
To assess the viability of BMDCs after incubation with
VCGs, the DCs were pulsed with VCG for 2 h, washed
and incubated further for 24 h and viability was assessed
using the XTT cell viability/proliferation assay according to
the manufacturer’s instructions (Cell Signaling Technology,
Danvers, MA). BMDCs (2 × 104/well) were incubated with
50 or 100 mg of VCGs/ml at 37°C for 2 h. The DCs werethen washed to remove excess VCGs followed by incuba-
tion in complete culture medium. After 24 h, premixed
XTT reagent was added to each well and cells were incu-
bated for an additional 4 h at 37°C. The absorbance was
measured at 450 nm using a Softmax plate reader after
thoroughly shaking the plate for 60 sec. The cytotoxic
agent Triton X-100 (0. 5%) was used as a control.
Fluorescent antibody staining and flow cytometry
Harvested BMDCs pulsed with VCG or UV-EB were
stained with monoclonal antibodies against CD11c, CD83,
CD86, CD14 or CD40, CD80, 1Ab, and CD71 conjugated
with either PE- or FITC (Pharmingen, San Diego, CA)
and analyzed by flow cytometry on a FACScan Flow
Cytometer (Becton-Dickinson, CA). Controls were in-
cubated with isotype-matched irrelevant antibodies.
Staining was carried out in PBS containing 5% FCS.
Marker expression was assessed on gated CD11c cells.
Assessment of antigen-specific CD4+ T cell responses
Splenocytes obtained from spleens of naïve and immune
mice (mice previously infected intranasally with 1 × 105
IFU of live Chlamydia) using the gentleMACS Dissocia-
tor (Miltenyi Biotech, Auburn, CA) were resuspended in
PBS containing BSA and EDTA. CD4+ T cells were then
purified by positive selection using the MidiMACS system
and labeled CD4 (L3T4) mouse microbeads (Miltenyi
Biotech, Auburn, CA). CD4+ T cell purity was at least >95%
by flow cytometry. BMDC (2 × 105 cells/well) pulsed with
UV-EB in the presence or absence of VCG for 24 h
were cultured with naïve or immune CD4+ T cells at
2 × 105 cells/well. Control cultures contained BMDCs
and naïve T cells. After 48 h, supernatants were har-
vested and assayed for Th1/Th2 cytokines using the
Bio-Plex cytokine assay kit in combination with the
Bio-Plex Manager software (Bio-Rad, Hercules, CA).
The mean and SD of all replicate cultures were calcu-
lated. The experiment was repeated three times.
Measurement of T cell proliferation
Purified Chlamydia-induced immune CD4+ T cells
(2 × 105 cells/well) were cultured in 96-well plates
(Corning Glass Work, Acton, MA) with 2 × 105 cells/
well of BMDCs alone or BMDCs previously pulsed for
24 h with VCG in 200 μl of C-RPMI medium supple-
mented with GM-CSF in the presence of chlamydial anti-
gen (106 IFU/ml UV-irradiated EBs) at 37°C in 5% CO2.
After three days, proliferation was assessed by the 5-Bromo-
2′-deoxy-uridine (BrdU) cell proliferation assay described
previously [20] according to the manufacturer’s instructions
(Roche Molecular Biochemicals, Indianapolis, IN). T cells
cultured in the absence of chlamydial antigen served as
internal control.
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protective immunity
Dendritic cells (JAWS II cells; 1×106 cells/ml) were incu-
bated with MEM medium containing L-glutamine, ribonu-
cleosides and deoxyribonucleosides (HyClone, Logan, Utah)
supplemented with 5 ng/ml murine GM-CSF (MEMS),
UV-EB (1×106 IFU/ml) or UV-EB + VCG (100 μg/ml)
at 37°C. After 24 h, the UV-EB or UV-EB + VCG-
pulsed DCs were washed three times with cold PBS
and injected subcutaneously into mice twice, 2 weeks
apart at a concentration of 1×106 cells/mouse in 25 μl
PBS. Six days before challenge, mice were treated with
2.5 mg/mouse Depo-Provera (Pfizer/UpJohn Co.,
Kalamazoo, MI) to synchronize estrous and challenged
intravaginally 2 weeks after the last immunization with
5 × 104 IFU of C. trachomatis serovar E in 5 μl of SPG
buffer. To assess the level of infection, cervicovaginal
swabs collected every 3 days following challenge were
incubated on HeLa cell monolayers grown on glass
cover slips in 24-well plates. Cells were fixed with 2%
paraformaldehyde and stained using a genus-specific
rabbit monoclonal antibody and FITC labeled goat
anti-rabbit secondary antibody. The number of inclusions
was counted under an Olympus B-Max microscope in
10–12 random fields. The mean ± SD of recovered chla-
mydial IFU per group was calculated.
On day 24-post challenge, serum samples were col-
lected by heart bleed and total T cells were purified from
the spleens of challenged mice.Detection of antibody isotype levels by ELISA
Blood samples were collected by heart puncture and va-
ginal lavage was obtained by flushing the vaginal vault
with 100 μl of PBS on day 24 after challenge. The
amount of specific antibodies (IgG2a and secretory IgA)
in sera and vaginal washes against chlamydial antigen was
measured by a standard ELISA procedure described previ-
ously [21]. Plates were incubated with HRP-conjugated
goat anti-mouse IgA, IgG1or IgG2c isotype (Southern
Biotechnology Associates, Inc., Birmingham, Ala.) for 1 h
and developed with (3,3′,5,5′-tetramethylbenzidine) (TMB).
The optical density was measured at 450 nm on a Micro-
plate reader. Results, generated simultaneously with a stand-
ard curve, display data sets corresponding to absorbance
values as mean concentrations (ng/ml) ± SD and represent
the mean values from triplicate experiments.Statistical analysis
Statistical analyses were performed with the GraphPad
Prism package (GraphPad Software, Inc. La Jolla, CA,
USA) on a Macintosh computer. The statistical signifi-
cance of the difference between two groups was evalu-
ated by Student’s t-test and between more than twogroups by one-way ANOVA. Differences were consid-
ered to be significant at p* < 0.05 or p** < 0.01.
Results
JAWS II DCs efficiently phagocytose (internalize) VCGs
The ability of JAWS II DC to internalize VCG was inves-
tigated by culture of Alexa 594 (red)- labeled DCs with
Alexa 488 (green)-labeled VCG. Before incubation with
antibodies, DC + VCG cultures were washed several times
by centrifugation at 300 g to remove non-internalized
VCG and ensure that only the cell-associated ones are
retained. The presence of internalized Alexa 594-labeled
VCG was captured on a Leica scanning confocal
microscope with a 40× (A-C) or 63× oil (D-F) objective
(Figure 1). VCGs were efficiently internalized following
co-incubation with DCs for 45 min (Figure 1C & F). How-
ever, detectable internalization was observed as early as
10 min after co-culture of VCG with the DC cultures
(data not shown).
VCG have no cytotoxic effect on cultured BMDCs
The effect of internalized VCG on the viability of BMDCs
was assessed after incubation of BMDCs with 50 μg and
100 μg of VCG for 2 h. The nonradioactive XTT colori-
metric assay was performed 24 h later to investigate pos-
sible toxic effects of VCGs on DCs. The results showed
VCG had no cytotoxic effects on the viability of BMDCs
at both concentrations (Figure 2). No significant differ-
ences in viability of BMDCs incubated with and without
VCG were detected. In contrast, there was a significant
decrease in the viability of BMDCs incubated under the
same conditions with the cytotoxic agent Triton X-100.
VCG enhanced the activation and maturation of BMDCs
Purified BMDCs were pulsed ex vivo either with UV-
irradiated chlamydial EBs (UV-EBs) or VCG or UV-EBs
together with VCG or culture medium alone (CM,
control) for 24 h and changes in surface activation
marker expression, including CD40, CD80, CD83, CD86
and MHC II (IAb) were assessed by FACS analysis.
Figure 3A shows that following overnight incubation,
UV-EBs up-regulated the expression of co-stimulatory
molecules involved in DC activation and maturation,
including CD80, CD86, MHC class II, CD40 and CD83.
This up-regulation was further enhanced following
co-incubation with VCGs or VCG alone. In contrast,
incubation of DC with antigens resulted in similar or
decreased expression of CD14 and CD71 compared to in-
cubation with CM alone. Figure 3B shows the percentage
number of cells positive for the indicated markers follow-
ing incubation with antigens or CM. These results reveal
that pulsing of BMDCs with the antigens lead to develop-
ment of the DC into a mature phenotype as indicated by
(A) (B) (C) 
(D) (E) (F) 
Figure 1 Uptake and internalization of VCGs by JAWS II dendritic cells (DCs). Internalization of fluorescence-labeled VCGs by JAWS II DCs
and localization of VCGs within DCs were visualized by confocal scanning microscopy. DCs were incubated on Chamber slides for 45 min with
100 μg/ml of Alexa 594-labeled VCGs. Following extensive washing with PBS-BSA, cells were fixed in cold acetone and incubated with biotin-labeled
anti-mouse CD11c antibodies and streptavidin-conjugated Alexa 488. Images were captured with a Leica scanning microscope with a 40x (A-C) or 63x oil
(D-F) objective and each image is a representative of a single z-stack of various optical sections. (A & D) Alexa 488-labeled DCs, (B & E) Alexa
594-labeled VCGs, and (C & F) internalized VCGs shown as yellow or greenish yellow particles, which represent direct overlay of green and























Figure 2 Effect of VCGs on dendritic cell viability. The viability of
BMDCs after incubation with VCGs was assessed using the XTT cell
viability/proliferation assay. BMDCs cultured in 96-well flat-bottom
plates (2 × 104/well, BD Biosciences) were incubated with 50 μg/ml
or 100 μg/ml of VCGs for 2 h. The XTT cell viability assay was performed
24 h later to investigate the toxicity of VCGs on BMDCs. Results are
expressed as absorbance values of VCG-pulsed cells relative to media
alone and the bars represent the mean and S.D. of three independent
experiments. Significant difference between cultures incubated with
media alone or cultures incubated with VCGs and Triton X-100 is
indicated by asterisk (P** <0.001).
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cules associated with DC activation and maturation.
VCG enhanced the production of Th1 promoting
cytokines by BMDCs
Culture supernatants of BMDCs pulsed ex vivo with
UV-EBs, UV-EB + VCG, or medium for 24 h were assayed
for the production of Th1/Th2-promoting cytokines
(IL-12, IL-10 and IL-4) as well as TNF-α by cytokine
ELISA and the results are shown in Figure 4. BMDCs
pulsed with VCG or UV-EBs displayed significantly (p ≤0.01)
increased levels of IL-12 and TNF-α but not IL-10 and IL-4
compared to BMDCs pulsed with medium alone (Figure 4).
Levels of IL-12 and TNF-α secreted were significantly
(p ≤0.01) enhanced when BMDCs were pulsed with
UV-EBs + VCG. These results suggest that VCGs en-
hanced the production of Th1 promoting cytokines by
BMDCs are thus capable of priming a robust Th1
response.
VCG enhanced BMDC presentation of chlamydial antigen
to immune CD4+ T cells
To assess the effect of VCG on the capacity of BMDCs
to process and present antigen to T cells, BMDCs
pulsed with UV-EBs with and without VCG for 24 h
were co-cultured with splenic CD4+ T cells from immune
and naïve mice for 48 h and the amount of secreted














































































































































































































Figure 3 Effect of VCG on activation marker expression by BMDCs using FACS analysis. Bone marrow-derived DCs (BMDCs) were isolated
from mice by established procedures using IL-4 and GM-CSF and characterized as loosely adherent mononuclear cells expressing high levels of
CD11c but lacking B220 surface antigens. Harvested cells were pulsed with VCGs or UV-EBs or UV-EBs + VCGs for 24 h, stained with conjugated
monoclonal antibodies against CD11C, CD40, CD80, CD83, CD86, 1Ab, CD14 and CD71 or isotype-matched controls, and quantified in triplicate
by flow cytometry. The data shows the mean fluorescence intensity of staining (A) and percentage of cells (B) expressing the indicated marker
after treatment with antigens (unshaded area) or culture media (Blue shaded area). Data is from one of two experiments with similar results.
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natants from BMDC cultures incubated with immune
CD4+ T cells produced significantly (p ≤0.01) higher
amounts of IFN-γ (a Th1-type cytokine) compared to
IL-4 (a Th2 cytokine) (Figure 5A). Importantly, the
amount of IFN-γ produced by CD4+ T cells restimulatedwith UV-EBs in the presence of VCG was significantly
(p ≤0.05) higher than that incubated with UV-EBs
alone. On the other hand, incubation of naïve CD4+ T cells
with BMDCs pulsed with UV-EBs in the presence or ab-
sence of VCG did not produce measurable amounts of cy-
tokines (Figure 5B). Also, CD4+ T cells incubated with
Figure 4 Effect of VCG on the production of Th1/Th2 promoting
cytokines by BMDCs. BMDCs were pulsed ex vivo with UV-EBs, UV-EB +
VCG, or medium for 24 h. Culture supernatants were collected and
assayed for IL-12, TNF-α, IL-10 and IL-4 cytokines by cytokine ELISA
using the Bio-Plex cytokine assay kit in combination with the Bio-Plex
Manager software. The concentration of the cytokines in each sample
was obtained by extrapolation from a standard calibration curve
generated simultaneously. Data are shown as the mean values (± S.D.)
for triplicate cultures for each experiment. The results are from two
independent experiments. Statistically significant differences between
DCs alone and treatment groups was evaluated at (p* < 0.05)
or (p** < 0.01).
A
B
Figure 5 Effect of VCG on BMDC presentation of chlamydial antigen
to immune and naïve CD4+ T cells. BMDC (2 × 105 cells/well) pulsed
for 24 h with UV-EB in the presence or absence of VCG were cultured
with purified immune (A) or naïve (B) CD4+ T cells (2 × 105 cells/well)
for 48 h. Control cultures contained BMDCs and purified T cells without
antigen (DC alone; DC+CM). At the end of the incubation period,
supernatants were harvested and assayed for Th1 and Th2 cytokines,
using the Bio-Plex cytokine assay kit in combination with the Bio-Plex
Manager software. The concentration of the cytokine in each sample
was obtained by extrapolation from a standard calibration curve
generated simultaneously. Data were calculated as the mean values
(± S.D.) for triplicate cultures for each experiment. The results are from
two independent experiments. Significant differences between DCs
alone and treated DCs and between DCs pulsed with UV-EB with and
without VCG are indicated by two asterisks (P <0.01) and an asterisk
(P <0.05) respectively.
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produce appreciable levels of cytokines (Figure 5). These
results indicate that chlamydial antigen presentation to
immune CD4+ T cells by BMDCs is enhanced by VCG,
leading to the production of significantly (p ≤0.05) higher
levels of IFN-γ.
VCG enhanced the proliferation of immune CD4+ T cells
in response to restimulation by UV-EBs
Immune CD4 T cells were incubated with BMDC
pulsed with either UV-EB or UV-EB + VCG or VCG
and T cell proliferation was assessed by the 5-Bromo-
2′-deoxy-uridine cell proliferation assay. The mean
absorbance values were 0.8800 ± 0.0820 (T cells + UV-EB)
1.837 ± 0.052 (T cells + UV-EB + VCG); 0.2875 ± 0.026
(T cells + VCG) and 0.25070 ± 0.0350 (T cells without
UV-EB, control)]. To determine the effect of VCG on
specific T cell proliferation, we analyzed stimulation
index (SI) values (the ratio between absorbance values
of stimulated and non-stimulated cells) obtained after
stimulation of CD4+ T cells with chlamydial antigen
(UV-EB) in the presence or absence of VCG. The de-
rived SI values are shown Figure 6A. The results show
that CD4+ T cells cultured with UV-EB + VCG prolif-
erated significantly higher (p < 0.01) than those cul-
tured with UV-EB alone. In contrast, T cells culturedwith VCG without chlamydial EBs did not proliferate
significantly.
We further investigated if VCG could also influence
the ability of naïve CD4 T cells to proliferate in the pres-
ence of chlamydial antigen (UV-EB). Thus, naïve CD4 T
AB
Figure 6 Effect of VCG on the proliferation of immune or naïve
CD4+ T cells. Purified Chlamydia sensitized CD4+ immune (A) or naïve
(B) T cells were cultured with BMDCs or VCG-pulsed BMDCs for 24 h and
restimulated in vitro with chlamydial antigen (106 IFU/ml UV-irradiated EBs)
for 3 days. The antigen-specific proliferative response was determined
using the BrdU incorporation assay; incorporation was detected by
addition of ABTS substrate and the optical density was read at 405 nm
using a scanning multi-well spectrophotometer. Results are expressed as
the stimulation index (SI), the ratio between absorbance values of
stimulated and non-stimulated cells and the bars represent the
mean and S.D. of three independent experiments. **p < 0.001 (BMDCs
versus BMDCs + EBs; BMDCs + EBs + VCG).
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UV-EB + VCG or VCG alone and T cell proliferation
was assessed by the XTT cell proliferation assay. Derived
SI values calculated from the mean absorbance values
are shown in Figure 6B. The results showed that unlike
immune CD4 T cells, naïve CD4 T cells did not prolifer-
ate significantly until day 6 following stimulation with
the various antigens. In contrast with immune T cells,VCG had no effect on the ability of T cells to proliferate
following stimulation with UV-EB. As expected, naïve
T cells cultured with VCG without chlamydial EBs did
not proliferate significantly. The results indicate that
VCG enhanced BMDC-mediated chlamydial antigen
presentation to immune but not naïve CD4+ T cells as
measured by T cell proliferative responses.
VCG enhanced the specific immune responses elicited
after challenge of immunized mice
The induction of antigen-specific antibody and cytokine
responses was evaluated 24 days after challenge of adop-
tively immunized mice. Mice immunized with the DC +
UV-EB + VCG elicited significantly higher (P < 0.05) levels
of serum IgG2c antibodies compared to DC +UV-EB or
DC controls. Although vaginal IgA levels elicited in the
presence of VCG were not significantly different from the
groups immunized without it, its presence showed a clear
immunogenic advantage (Figure 7A). Total T cells purified
from the spleen were cultured with γ-irradiated APCs and
stimulated in vitro with UV-EBs (chlamydial antigen).
IFN-γ and IL-4 production in supernatant cultures were
measured by cytokine ELISA. The results showed that
mice vaccinated with DC + UV-EB + VCG produced
significantly (p ≤0.05) higher chlamydial-specific IFN-γ
(1107.107 ± 58.67 pg/ml) compared to mice immunized
with DC +UV-EB (324.273 ± 17.39) or DCs alone (169.857)
(Figure 7B).
VCG enhanced the ability of adoptively immunized mice
to resolve a chlamydial genital infection
Immunized mice were challenged intravaginally with live
Chlamydia 24 days after the last immunization and peri-
odically monitored for clearance. Figure 8 shows that
mice that received DC +UV-EB + VCG shed fewer chla-
mydial IFUs after intravaginal challenge with live Chla-
mydiae compared to mice that received DC alone or
cells without VCG.
Discussion
The novel VCG platform is an effective carrier/delivery
system for vaccine antigens, promoting the induction of
significant immunity in the absence of external adjuvants,
suggesting that VCGs possess potent immunostimulatory/
adjuvant properties [12,13,22]. We hypothesized that the
immunostimulatory ability of VCG is exerted via DC acti-
vation. DCs are potent antigen presenting cells that are es-
sential for the initiation of primary immune responses,
especially those essential in priming the differentiation of
naïve T cells to Th1 or Th2 sub-types [23,24]. Efficient
antigen uptake by antigen presenting cells (APCs), espe-
cially by professional APCs such as DCs, processing and
presentation is a prerequisite for directing T- and B-cells
towards the desired immune responses. The phenotypic
AB
Figure 7 Memory antibody and Th1/Th2 cytokine responses
elicited 24 days postchallenge. Groups of mice were adoptively
immunized and challenged intravaginally as described in the
materials and methods section. About 24 days postchallenge, serum,
vaginal lavage and spleens were collected. The amount of memory
antibodies (A) elicited in genital lavage and serum was assessed by
an antibody ELISA. Results generated simultaneously with a standard
curve display data sets corresponding to absorbance values as mean
concentrations (ng/ml) ± SD of triplicate cultures for each experiment.
The results are from two independent experiments. *Statistically
significant (p < 0.05) differences between DC + EB and DC + EB + VCG
groups. Also, purified splenic T cells were restimulated in vitro
with UV-irradiated chlamydial EBs and IFN-γ and IL-4 production
were assessed as a measure of Thl and Th2 responses, respectively. The
amount of cytokine contained in supernatants of culture-stimulated
cells was measured by single cytokine ELISA. The concentration of the
cytokine in each sample was obtained by extrapolation from a
standard calibration curve generated simultaneously. Data were
calculated as the mean values (± S.D.) for triplicate cultures for
each experiment (B). The results are from two independent
experiments. *Statistically significant (p < 0.05) differences between
DC + EB and DC + EB + VCG groups.




























Figure 8 Effect of VCG on reduction of IFU in adoptively
immunized mice. Immunized mice were challenged intravaginally
with 5 x 104 IFU of live chlamydiae 24 days after the last
immunization. One week prior to challenge, mice were administered
Depo Provera to stabilize the estrous cycle and facilitate a
productive infection. Infections were monitored by cervicovaginal
swabbing of individual animals every 3 days and Chlamydia was
isolated from swabs in tissue culture and enumerated. The data
show the mean recoverable IFUs ± S.D. The experiment was
repeated to contain 6 mice per group.
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are intimately linked to their stage of maturation. Thus,
upon activation and maturation, antigen-loaded DCs initi-
ate antigen-specific immunity leading to T cell prolifera-
tion and differentiation into helper and effector cells with
unique functions [25]. To analyze the mechanism by
which VCGs boost anti-chlamydial immune responses
through DC activation, we evaluated the ability of BMDCs
to internalize VCGs and its effect on DC viability, matur-
ation, and presentation of chlamydial antigen to CD4+ T
cells. Our results showed that VCGs are efficiently inter-
nalized by DCs without affecting their viability. This is
consistent with a previous report showing that human
conjunctival epithelial cells have a high capacity to func-
tionally internalize bacterial ghosts without any cytotoxic
effects [26].
The present study used UV-EBs with or without VCGs
to stimulate DC maturation. The interaction of VCGs
with BMDC stimulated the expression of co-stimulatory
molecules associated with DC activation and maturation.
In addition, there is enhanced expression of major histo-
compatibility complex molecules (MHC) and these sur-
face molecules mediate adhesion with T cells during
antigen presentation [27]. Consistent with previous find-
ings [28], stimulation of BMDCs with UV-EBs for 24 h
resulted in the significant up-regulation of costimulatory
molecules (CD40, CD80, CD83 and CD86) and class II
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that was enhanced by co-culture with VCGs. These mol-
ecules are well-recognized markers for mature dendritic
cells and may be involved in regulation of antigen pres-
entation. We found no change in the expression of the
transferrin receptor, CD71 and the monocyte lineage
marker CD14 consistent with previous findings indicat-
ing stimulation of BMDCs with a VCG-based vaccine re-
sulted in decrease in expression of CD14 and CD71 [29].
CD71 is essential for cellular growth and is usually
expressed by immature proliferating cells and at low
levels on resting mature lymphocytes. CD14 is expressed
by monocytes, macrophages and immature DCs but not
by mature DCs [30,31]. The low expression of CD14 and
CD71 by VCG-pulsed DCs confirms that these DCs are in
a fully activated and mature state. Also, the inability of
VCG to induce DCs to express CD14 confirms previous
findings by Haselberger et al. [32] indicating that LPS in
the intact Gram-negative cellular envelop does not possess
the same stimulatory and pyrogenic potential as purified
LPS. This will explain the observation that repeated
systemic administration of VCG even in very high
doses fail to induce pyrogenic effects in experimental
animals [29,33].
VCG activation of BMDC enhanced the secretion of
proinflammatory cytokines, particularly IL-12 and TNF-
α and chlamydial antigen presentation to infection-
sensitized CD4+ T cells leading to enhanced prolifera-
tion and secretion of Th1-type cytokines. These findings
are consistent with the report of a recent study showing
that a VCG-based chlamydial vaccine induced enhanced
proinflammatory cytokine production by BMDCs [29].
Inflammation is a fundamental defense response, and is
associated with the secretion of proinflammatory and
anti-inflammatory cytokines. IL-12 is naturally produced
by DCs in response to antigenic stimulation, and is
critical for directing the differentiation of naïve T cells
into Th1 cells [34] and effective protection against
genital chlamydial infection [35] due to its role in indu-
cing T cells to produce IFN-γ. The secretion of IL-12 by
activated BMDCs suggests a possible mechanism by
which VCG-based vaccines enhance CD4+ Th1 immune
responses in vivo. VCG also significantly enhanced the pro-
liferation of Chlamydia-specific CD4+ T cells and IFN-γ
secretion in response to in vitro restimulation with chla-
mydial antigen as reported previously [20]. Studies of pro-
tective immunity in the murine model of C. trachomatis
genital infection demonstrated that an MHC class II re-
stricted CD4+ Th1 response is critical for resolving pri-
mary chlamydial infection [36,37].
Another significant finding of this study is the capacity of
VCG to enhance the immunogenicity and protective ability
of adoptively administered DC-based cellular vaccine. The
results showed that co-delivery of antigen-pulsed DCs withVCG enhanced the chlamydial-specific antibody and T cell
responses that conferred protective immunity against chal-
lenge. It has been suggested that adjuvants act on DCs pos-
sibly by providing danger signals [38] that stimulate
cellular activation for an enhanced antigen handling
and presentation. Thus, previous studies showed that
VCG-based vaccines elicited enhanced cellular and humoral
immunity in the absence of external adjuvants [13,20].
The observed adjuvanticity of VCG may be due to its abil-
ity to provide danger signals related to the surface character-
istics of the Vibrio envelope complex. Since the morphology
of VCGs is not denatured during ghost production, all major
immune stimulating constituents of the envelope [10,39],
comprising LPS, Monophosphoryl lipid A (MPL), outer
membrane proteins, toxin co-regulated pili, peptidoglycan
or flagellin are preserved. Retention of these constituent im-
munomodulatory pathogen-associated molecular patterns
(PAMPs) that are recognized by toll-like receptors (TLRs)
contributes to the immunoenhancing potential of VCGs.
The V. cholerae cell envelope carrier system (VCG) is thus a
self-adjuvanting delivery platform naturally endowed with
potent adjuvant properties. Besides, VCGs have limited or
no toxicity that is commonly associated with the purified
LPS of Gram-negative bacteria. This obviates a potential
problem in using VCGs as vaccine carriers or adjuvants. In
fact, specific studies have shown that VCGs from V. cholerae
serotype Inaba, exhibited 1000-fold less endotoxin units
(EU) per ml than the purified LPS as analyzed by the Lim-
ulus Amoebocyte Lysate assay [32]. Also, previous immuno-
logic studies showed that E. coli, Salmonella typhimurium
and V. cholerae-derived bacterial ghosts are comparatively
less pyrogenic than LPS in rabbits [40]. Therefore, endotoxi-
city does not limit the use of the V. cholerae bacterial ghost
system as a vaccine carrier or adjuvant. Moreover, existing
and acceptable licensed human cholera vaccines are either
attenuated or inactivated whole V. cholerae cells with intact
living or nonliving gram-negative bacterial cell envelopes, re-
spectively and are nontoxic [41,42].
Conclusion
In the present work we demonstrated that VCGs are ef-
ficiently internalized by DCs without affecting their via-
bility and this interaction stimulated the expression by
DCs of co-stimulatory molecules associated with DC
maturation and secretion of proinflammatory cytokines.
This interaction also led to enhancement of chlamydial
antigen presentation to immune CD4+ T cells leading to
enhanced T cell proliferation and secretion of Th1-type
cytokines. Taken together, these results indicate that
the immunomodulatory function of VCG for increased
T-cell activation is mediated, at least in part, through
DC triggering suggesting that VCGs would be a prom-
ising tool as an immunomodulator to enhance type-1
immunity.
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